Skip to main content

IPILIMUMAB

Tracking # 20-811751

$99999.00

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

IPILIMUMAB IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF METASTATIC MELANOMA. IT IS IN THE CTLA-4 MONOCLONAL ANTIBODY CLASS OF MEDICATIONS. THIS ACTIVITY ILLUSTRATES THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR IPILIMUMAB AS A VALUABLE AGENT IN THE MANAGEMENT OF METASTATIC MELANOMA AND SEVERAL OTHER TUMORS. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., OFF-LABEL USES, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, RELEVANT INTERACTIONS) PERTINENT FOR MEMBERS OF THE HEALTHCARE TEAM IN THE MANAGEMENT OF PATIENTS WITH METASTATIC MELANOMA AND RELATED CONDITIONS.

Subject areas

This course counts toward the state boards and subject areas below.

Bahamas Medical Council

Specialty Medical Practitioner

1h General Medicine

Louisiana State Board of Medical Examiners - Physicians & Surgeons

Physician & Surgeon

1h Category I CME

Mississippi State Board of Medical Licensure

Medical Doctor

1h AMA Category I

Physician Assistant

1h AMA Category I

State Medical Board of Ohio

Doctor of Medicine

1h AMA Category I